Fabrication and evaluation of novel quercetin-conjugated Fe(3)O(4)–β-cyclodextrin nanoparticles for potential use in epilepsy disorder

BACKGROUND: Despite the numerous pharmacological activities of quercetin, its biomedical application has been hampered, because of poor water solubility and low oral bioavailability. In the present study, we fabricated a novel form of quercetin-conjugated Fe(3)O(4)–β-cyclodextrin (βCD) nanoparticles (NPs), and the effect of these prepared NPs was evaluated in a chronic model of epilepsy. METHODS: Quercetin-loaded NPs were prepared using an iron oxide core coated with βCD and pluronic F68 polymer. The chronic model of epilepsy was developed by intraperitoneal injection of pentylenetetrazole (PTZ) at dose of 36.5 mg/kg every second day. Quercetin or its nanoformulation at doses of 25 or 50 mg/kg were administered intraperitoneally 10 days before PTZ injections and their applications continued 1 hour before each PTZ injection. Immunostaining was performed to evaluate the neuronal density and astrocyte activation of hippocampi. RESULTS: Our data showed successful fabrication of quercetin onto Fe(3)O(4)–βCD NPs. In comparison to free quercetin, quercetin NPs markedly reduced seizure behavior, neuronal loss, and astrocyte activation in a PTZ-induced kindling model. CONCLUSION: Overall, quercetin–Fe(3)O(4)–βCD NPs might be regarded as an ideal therapeutic approach in epilepsy disorder.